Last reviewed · How we verify

NCT04622891

Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

Completed NA Last updated 10 November 2020
What this trial tests

NA trial testing Clarithromycin 500mg in Covid19 in 300 participants. Completed in 30 July 2020.

Timeline
1 April 2020
Primary endpoint
30 July 2020
30 July 2020

Quick facts

Lead sponsorSouth Valley University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment300
Start date1 April 2020
Primary completion30 July 2020
Estimated completion30 July 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

South Valley University

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
    Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
  2. Antibiotics for the treatment of COVID-19.
    Popp M, Stegemann M, Riemer M, Metzendorf MI, et al · · 2021 · cited 60× · PMID 34679203 · DOI 10.1002/14651858.cd015025
  3. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.
    Webster KE, O'Byrne L, MacKeith S, Philpott C, et al · · 2021 · cited 22× · PMID 34291812 · DOI 10.1002/14651858.cd013877.pub2
  4. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    O'Byrne L, Webster KE, MacKeith S, Philpott C, et al · · 2022 · cited 21× · PMID 36062970 · DOI 10.1002/14651858.cd013876.pub3
  5. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction.
    O'Byrne L, Webster KE, MacKeith S, Philpott C, et al · · 2021 · cited 21× · PMID 34291813 · DOI 10.1002/14651858.cd013876.pub2
  6. Therapeutic efficacy of macrolides in management of patients with mild COVID-19.
    Rashad A, Nafady A, Hassan MH, Mansour H, et al · · 2021 · cited 20× · PMID 34381155 · DOI 10.1038/s41598-021-95900-z
  7. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.
    Webster KE, O'Byrne L, MacKeith S, Philpott C, et al · · 2022 · cited 11× · PMID 36063364 · DOI 10.1002/14651858.cd013877.pub3
  8. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.
    Xue Y, Mei H, Chen Y, Griffin JD, et al · · 2023 · cited 9× · PMID 37193304 · DOI 10.1002/mco2.254

Verify or expand the search:

Other trials of Clarithromycin 500mg

Trials testing the same drug.

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other South Valley University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04622891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing